304 related articles for article (PubMed ID: 30579123)
21. Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.
Ouyang M; Zeng L; Huang H; Jin C; Liu J; Chen Y; Ji L; Chao H
Dalton Trans; 2017 May; 46(20):6734-6744. PubMed ID: 28488721
[TBL] [Abstract][Full Text] [Related]
22. Half-sandwich Iridium(III) Benzimidazole-Appended Imidazolium-Based N-heterocyclic Carbene Complexes and Antitumor Application.
Han Y; Liu X; Tian Z; Ge X; Li J; Gao M; Li Y; Liu Y; Liu Z
Chem Asian J; 2018 Dec; 13(23):3697-3705. PubMed ID: 30276978
[TBL] [Abstract][Full Text] [Related]
23. Triphenylamine-appended cyclometallated iridium(III) complexes: Preparation, photophysical properties and application in biology/luminescence imaging.
Liu X; Hao H; Ge X; He X; Liu Y; Wang Y; Wang H; Shao M; Jing Z; Tian L; Liu Z
J Inorg Biochem; 2019 Oct; 199():110757. PubMed ID: 31445461
[TBL] [Abstract][Full Text] [Related]
24. Significant effects of counteranions on the anticancer activity of iridium(iii) complexes.
Zhang H; Guo L; Tian Z; Tian M; Zhang S; Xu Z; Gong P; Zheng X; Zhao J; Liu Z
Chem Commun (Camb); 2018 Apr; 54(35):4421-4424. PubMed ID: 29648559
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, characterization, anticancer efficacy evaluation of ruthenium(II) and iridium(III) polypyridyl complexes toward A549 cells.
Liang L; Yang Y; Liu H; Yuan F; Yuan Y; Li W; Huang C; Chen J; Liu Y
J Biol Inorg Chem; 2023 Jun; 28(4):421-437. PubMed ID: 37097484
[TBL] [Abstract][Full Text] [Related]
26. Lysosome-targeted chemotherapeutics: Anticancer mechanism of N-heterocyclic carbene iridium(III) complex.
Zhang J; Liu J; Liu X; Liu B; Song S; He X; Che C; Si M; Yang G; Liu Z
J Inorg Biochem; 2020 Jun; 207():111063. PubMed ID: 32222581
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial targeting half-sandwich iridium(III) and ruthenium(II) dppf complexes and in vitro anticancer assay.
Liu J; Wu Y; Yang G; Liu Z; Liu X
J Inorg Biochem; 2023 Feb; 239():112069. PubMed ID: 36423395
[TBL] [Abstract][Full Text] [Related]
28. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
29. Half-sandwich iridium(III) complexes with α-picolinic acid frameworks and antitumor applications.
Hao H; Liu X; Ge X; Zhao Y; Tian X; Ren T; Wang Y; Zhao C; Liu Z
J Inorg Biochem; 2019 Mar; 192():52-61. PubMed ID: 30597449
[TBL] [Abstract][Full Text] [Related]
30. Organoiridium complexes: anticancer agents and catalysts.
Liu Z; Sadler PJ
Acc Chem Res; 2014 Apr; 47(4):1174-85. PubMed ID: 24555658
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, Characterization, and Biological Properties of Steroidal Ruthenium(II) and Iridium(III) Complexes Based on the Androst-16-en-3-ol Framework.
Koch V; Meschkov A; Feuerstein W; Pfeifer J; Fuhr O; Nieger M; Schepers U; Bräse S
Inorg Chem; 2019 Dec; 58(23):15917-15926. PubMed ID: 31714764
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes.
Guo L; Hu X; Yang Y; An W; Gao J; Liu Q; Liu Z
Bioorg Chem; 2021 Nov; 116():105311. PubMed ID: 34474302
[TBL] [Abstract][Full Text] [Related]
33. Preparation and the anticancer mechanism of configuration-controlled Fe(II)-Ir(III) heteronuclear metal complexes.
Shao M; Liu X; Sun Y; Dou S; Chen Q; Yuan XA; Tian L; Liu Z
Dalton Trans; 2020 Sep; 49(36):12599-12609. PubMed ID: 32857087
[TBL] [Abstract][Full Text] [Related]
34. Inert ruthenium half-sandwich complexes with anticancer activity.
Meggers E; Atilla-Gokcumen GE; Gründler K; Frias C; Prokop A
Dalton Trans; 2009 Dec; (48):10882-8. PubMed ID: 20023918
[TBL] [Abstract][Full Text] [Related]
35. Reactive Oxygen Species Production Is Responsible for Antineoplastic Activity of Osmium, Ruthenium, Iridium and Rhodium Half-Sandwich Type Complexes with Bidentate Glycosyl Heterocyclic Ligands in Various Cancer Cell Models.
Kacsir I; Sipos A; Bényei A; Janka E; Buglyó P; Somsák L; Bai P; Bokor É
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054999
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
37. Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents.
Laha P; De U; Chandra F; Dehury N; Khullar S; Kim HS; Patra S
Dalton Trans; 2018 Nov; 47(44):15873-15881. PubMed ID: 30358775
[TBL] [Abstract][Full Text] [Related]
38. An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway.
Tang B; Wan D; Wang YJ; Yi QY; Guo BH; Liu YJ
Eur J Med Chem; 2018 Feb; 145():302-314. PubMed ID: 29331753
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic Ru
Sarkar A; Acharya S; Khushvant K; Purkait K; Mukherjee A
Dalton Trans; 2019 May; 48(21):7187-7197. PubMed ID: 30601545
[TBL] [Abstract][Full Text] [Related]
40. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.
Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z
Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
